Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for aggression and disruptive behavior in children and adolescents with conduct disorder
NL-OMON38186Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in conduct disorder (CD) comparing Risperidone with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Apr 2012; status: not yet recruiting.
02
Drugs
risperidone
03
Conditions
conduct disorder (CD)
Beyond the preview
Go deeper on NL-OMON38186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38186.